Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa

Table 3 Summary of clinical findings (n = 50)

Clinical Findings	Baseline	Mid-cycle	One month post-treatment	p-value (Test for trend)*
Hearing loss^a
Bilateral	11 (22)	16 (32)	18 (36)	0.13
Left ear only	4 (8)	3 (6)	1 (2)	0.17
Right ear only	1 (2)	1 (2)	2 (4)	0.56
Type of hearing loss
Sensorineural	15 (30)	19 (38)	19 (38)	–
Conductive	0	0	0	–
Mixed	1 (2)	1 (2)	1 (2)	–
Ototoxic hearing loss^b	0	49 (98)	1 (2)
Bilateral
Left ear only
Right ear only

*Cochran-Armitage test for a linear trend in proportions
^aThe presence of a hearing loss was determined using the Silman and Silverman’s (1991) magnitude of hearing impairment. If thresholds exceeded 25 dB at more than three frequencies in the conventional frequency range, it was classified as a hearing loss
^bOtotoxic hearing loss was determined using the ASHA (1994) guidelines, which indicates the following: (a) ≥ 20 dB decrease at any one test frequency, (b) ≥10 dB decrease at any two adjacent frequencies, or (c) loss of response at three consecutive frequencies where responses were previously obtained

ISSN: 1471-2407